Several molecular changes have been found to contribute to the aggressiveness of IBC, including loss of WISP3 and overexpression of RhoC GTPase [2], E-cadherin [3], translation initiation factor eIF4GI [4], and tazarotene-induced gene 1 [5]. This evidence concerns the gene RHOC and inflammatory breast carcinoma.